The Experts below are selected from a list of 8268 Experts worldwide ranked by ideXlab platform
Xavier Badoux - One of the best experts on this subject based on the ideXlab platform.
-
high durable minimal residual disease negativity mrd with venetoclax rituximab venr in relapsed refractory r r cll mrd kinetics from phase 3 murano study
Journal of Clinical Oncology, 2018Co-Authors: Peter Hillmen, Sarit Assouline, Paula Marlton, Anton W Langerak, Barbara Eichhorst, Ann Janssens, Arnon P. Kater, John F Seymour, Carolyn Owen, Xavier BadouxAbstract:7508Background: Survival with Chemoimmunotherapy is associated with MRD–, but the importance of MRD with targeted agents and in R/R setting remains unclear, mostly due to low MRD– rates. In MURANO,...
-
High, durable minimal residual disease negativity (MRD–) with venetoclax + rituximab (VenR) in relapsed/refractory (R/R) CLL: MRD kinetics from phase 3 MURANO study.
Journal of Clinical Oncology, 2018Co-Authors: Peter Hillmen, Sarit Assouline, Paula Marlton, Anton W Langerak, Barbara Eichhorst, Ann Janssens, Arnon P. Kater, John F Seymour, Carolyn Owen, Xavier BadouxAbstract:7508Background: Survival with Chemoimmunotherapy is associated with MRD–, but the importance of MRD with targeted agents and in R/R setting remains unclear, mostly due to low MRD– rates. In MURANO,...
Peter Hillmen - One of the best experts on this subject based on the ideXlab platform.
-
high durable minimal residual disease negativity mrd with venetoclax rituximab venr in relapsed refractory r r cll mrd kinetics from phase 3 murano study
Journal of Clinical Oncology, 2018Co-Authors: Peter Hillmen, Sarit Assouline, Paula Marlton, Anton W Langerak, Barbara Eichhorst, Ann Janssens, Arnon P. Kater, John F Seymour, Carolyn Owen, Xavier BadouxAbstract:7508Background: Survival with Chemoimmunotherapy is associated with MRD–, but the importance of MRD with targeted agents and in R/R setting remains unclear, mostly due to low MRD– rates. In MURANO,...
-
High, durable minimal residual disease negativity (MRD–) with venetoclax + rituximab (VenR) in relapsed/refractory (R/R) CLL: MRD kinetics from phase 3 MURANO study.
Journal of Clinical Oncology, 2018Co-Authors: Peter Hillmen, Sarit Assouline, Paula Marlton, Anton W Langerak, Barbara Eichhorst, Ann Janssens, Arnon P. Kater, John F Seymour, Carolyn Owen, Xavier BadouxAbstract:7508Background: Survival with Chemoimmunotherapy is associated with MRD–, but the importance of MRD with targeted agents and in R/R setting remains unclear, mostly due to low MRD– rates. In MURANO,...
Arnon P. Kater - One of the best experts on this subject based on the ideXlab platform.
-
high durable minimal residual disease negativity mrd with venetoclax rituximab venr in relapsed refractory r r cll mrd kinetics from phase 3 murano study
Journal of Clinical Oncology, 2018Co-Authors: Peter Hillmen, Sarit Assouline, Paula Marlton, Anton W Langerak, Barbara Eichhorst, Ann Janssens, Arnon P. Kater, John F Seymour, Carolyn Owen, Xavier BadouxAbstract:7508Background: Survival with Chemoimmunotherapy is associated with MRD–, but the importance of MRD with targeted agents and in R/R setting remains unclear, mostly due to low MRD– rates. In MURANO,...
-
High, durable minimal residual disease negativity (MRD–) with venetoclax + rituximab (VenR) in relapsed/refractory (R/R) CLL: MRD kinetics from phase 3 MURANO study.
Journal of Clinical Oncology, 2018Co-Authors: Peter Hillmen, Sarit Assouline, Paula Marlton, Anton W Langerak, Barbara Eichhorst, Ann Janssens, Arnon P. Kater, John F Seymour, Carolyn Owen, Xavier BadouxAbstract:7508Background: Survival with Chemoimmunotherapy is associated with MRD–, but the importance of MRD with targeted agents and in R/R setting remains unclear, mostly due to low MRD– rates. In MURANO,...
Ann Janssens - One of the best experts on this subject based on the ideXlab platform.
-
high durable minimal residual disease negativity mrd with venetoclax rituximab venr in relapsed refractory r r cll mrd kinetics from phase 3 murano study
Journal of Clinical Oncology, 2018Co-Authors: Peter Hillmen, Sarit Assouline, Paula Marlton, Anton W Langerak, Barbara Eichhorst, Ann Janssens, Arnon P. Kater, John F Seymour, Carolyn Owen, Xavier BadouxAbstract:7508Background: Survival with Chemoimmunotherapy is associated with MRD–, but the importance of MRD with targeted agents and in R/R setting remains unclear, mostly due to low MRD– rates. In MURANO,...
-
High, durable minimal residual disease negativity (MRD–) with venetoclax + rituximab (VenR) in relapsed/refractory (R/R) CLL: MRD kinetics from phase 3 MURANO study.
Journal of Clinical Oncology, 2018Co-Authors: Peter Hillmen, Sarit Assouline, Paula Marlton, Anton W Langerak, Barbara Eichhorst, Ann Janssens, Arnon P. Kater, John F Seymour, Carolyn Owen, Xavier BadouxAbstract:7508Background: Survival with Chemoimmunotherapy is associated with MRD–, but the importance of MRD with targeted agents and in R/R setting remains unclear, mostly due to low MRD– rates. In MURANO,...
Barbara Eichhorst - One of the best experts on this subject based on the ideXlab platform.
-
high durable minimal residual disease negativity mrd with venetoclax rituximab venr in relapsed refractory r r cll mrd kinetics from phase 3 murano study
Journal of Clinical Oncology, 2018Co-Authors: Peter Hillmen, Sarit Assouline, Paula Marlton, Anton W Langerak, Barbara Eichhorst, Ann Janssens, Arnon P. Kater, John F Seymour, Carolyn Owen, Xavier BadouxAbstract:7508Background: Survival with Chemoimmunotherapy is associated with MRD–, but the importance of MRD with targeted agents and in R/R setting remains unclear, mostly due to low MRD– rates. In MURANO,...
-
High, durable minimal residual disease negativity (MRD–) with venetoclax + rituximab (VenR) in relapsed/refractory (R/R) CLL: MRD kinetics from phase 3 MURANO study.
Journal of Clinical Oncology, 2018Co-Authors: Peter Hillmen, Sarit Assouline, Paula Marlton, Anton W Langerak, Barbara Eichhorst, Ann Janssens, Arnon P. Kater, John F Seymour, Carolyn Owen, Xavier BadouxAbstract:7508Background: Survival with Chemoimmunotherapy is associated with MRD–, but the importance of MRD with targeted agents and in R/R setting remains unclear, mostly due to low MRD– rates. In MURANO,...